a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham ...
The team believes that the structure was in use until the 8th century BCE, the middle of the period when the Kings of Judah ruled. A scarab seal from the 8th century BCE uncovered during the ...
Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025 Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025 ...
TULISOKIBART, a tumour necrosis factor–like cytokine 1A (TL1A) monoclonal antibody, has demonstrated significant potential in inducing clinical remission in patients with moderately-to-severely active ...
Earth's inner core may actually have two distinct layers. (alexlmx/Canva Pro) "We found evidence that may indicate a change in the structure of iron, which suggests perhaps two separate cooling events ...
1月9日，步长制药公告，全资子公司保定天浩制药有限公司近日收到国家药品监督管理局核准签发的关于磷酸奥司他韦干混悬 ...
来自MSN1 个月
编辑: 梁枭 记者: 林姿辰 的报道1月9日，步长制药公告，全资子公司保定天浩制药有限公司近日收到国家药品监督管理局核准签发的关于磷酸奥司他韦干混悬剂的《药品注册证书》。公告显示，该产品可用于2周龄及以上年龄患者的甲型和乙型流感治疗，患者应在首次出现症状48小时以内使用 ...
TL1A（TNF配体相关分子1A）是肿瘤坏死因子超家族的成员，主要由内皮细胞表达。它与DR3（死亡受体3）结合，为下游信号通路提供刺激信号，调节效应 ...
TL1A（TNF配体相关分子1A）是肿瘤坏死因子超家族的成员，主要由内皮细胞表达。它与DR3（死亡受体3）结合，为下游信号通路提供刺激信号，调节效应 ...
TL1A（TNF配体相关分子1A）是肿瘤坏死因子超家族的成员，主要由内皮细胞表达。它与DR3（死亡受体3）结合，为下游信号通路提供刺激信号，调节效应 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈